Advertisement

Labormedizin pp 375-392 | Cite as

Tumormarker

  • Gabriele Halwachs-Baumann
Chapter
  • 5.4k Downloads

Auszug

Als Tumormarker werden Substanzen bezeichnet, deren Auftreten und Konzentrationsänderung in gewisser Beziehung mit der Entstehung und dem Wachstum von malignen Tumoren eines Individuums stehen. Es wäre von großem Vorteil, wenn es mit Hilfe eines einfachen Labortestes möglich wäre, ein Karzinom zu einem frühen, daher noch heilbaren Stadium, zu diagnostizieren. Auf alle Fälle in einem Stadium in dem noch keine Metastasen aufgetreten sind. Einen derartigen Test gibt es aber leider noch nicht. Dazu kommt, dass die Tumormarker-Spiegel in Körperflüssigkeiten (Blut, Harn etc.) auch bei benignen Erkrankungen, oder durch präanalytische Einflussgrößen erhöht sein können. Tumormarker sind daher als Screeningparameter (mit wenigen Ausnahmen) nicht geeignet! (1, 2, 3, 4).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Allgemein

  1. Thomas L (1998) Labor und Diagnose. TH-Books Verlagsgesellschaft mbH, Frankfurt/MainGoogle Scholar

Speziell

  1. 1.
    Joss R, Cerny T (1990) Sinn und Unsinn von Tumormarkern in der Praxis. Schweiz Med Wschr 120: 693–703PubMedGoogle Scholar
  2. 2.
    Bates S E, Longo D L (1985) Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 12(3): 163–207PubMedCrossRefGoogle Scholar
  3. 3.
    Berlin N I (1981) Tumor markers in cancer prevention and detection. Cancer 47[5 Suppl]: 1151–1153PubMedCrossRefGoogle Scholar
  4. 4.
    Pavlidis N, Kalef-Ezra J, Briassoulis E, Skarlos D, Kosmidis P, Saferiadis K, Bairaktari E, Bafaloukos D, Maravegias A, Theoharis D (1994) Evaluaton of six tumor markers in patients with varcinoma of unknown primary. Med Pediatr Oncol 22(3):162–167PubMedCrossRefGoogle Scholar
  5. 5.
    Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48(8): 1151–1159PubMedGoogle Scholar
  6. 7.
    Sturgeon C (2001) Tumor markers in the laboratory: closing the guideline-practice gap. Clin Biochem 34: 353–359PubMedCrossRefGoogle Scholar
  7. 8.
    Soletormos G, Schioler V, Nielsen D, Skovsgaard T, Dombernowsky P (1993) Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 39(10): 2077–2083PubMedGoogle Scholar
  8. 9.
    Tuxen M K, Söetormos G, Petersen P H, Schioler V, Dombernowsky P (1999) Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gyn One 74: 12–22CrossRefGoogle Scholar
  9. 10.
    Plebani M, Giacomini A, Beghi L, de Paoli M, Roveroni G, Galeotti F, Vorsini A, Fraser CG (1996) Serum tumor markers in monitorino patients: interpretation of results using analytical and biological variation. Anti-cancer Res 16(4B): 2249–2252Google Scholar
  10. 11.
    Nap M, Mollgard K, Burtin P, Fleuren G J (1988) Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 9(2–3): 145–153PubMedCrossRefGoogle Scholar
  11. 12.
    Fukuda I, Yamakado M, Kiyose H (1998) Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst 22(2): 89–93PubMedCrossRefGoogle Scholar
  12. 13.
    Ohwada A, Takahashi H, Nagaoka I, Iwabuchi K, Mikami O, Kira S (1995) Effect of cigarette smoke on the mRNA and protein expression of carcinoembryonic antigen (CEA), a possible chemoattractant for neutrophils in human bronchioalveolar tissues. Thorax 50(6): 651–657PubMedCrossRefGoogle Scholar
  13. 14.
    Lurie B B, Loewenstein M S, Zamcheck N (1975) Elevated carcinoembryonic antigen levels and biliary tract obstruction. JAMA 233(4): 326–330PubMedCrossRefGoogle Scholar
  14. 15.
    Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol M D (2004) The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 51(59): 1544–1547PubMedGoogle Scholar
  15. 16.
    Duffy M J (2001) Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 47(4): 624–630PubMedGoogle Scholar
  16. 17.
    Anonymous (1996) Clinical practice guidelines fort he use of tumor markers in breast and colorectal cancer. J Clin Oncol 14(10): 2843–2877Google Scholar
  17. 18.
    Chalasani N, Horlander J C, Said A, Hoen H, Kopecky K K, Stockberger S M, Manam R, Kwo P Y, Lumeng L (1999) Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 94: 2988–2993PubMedCrossRefGoogle Scholar
  18. 19.
    Gambarin-Gelwan M, Wolf D C, Shapiro R, Schwartz M W, Min A D (2000) Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 95(6): 1535–1538PubMedCrossRefGoogle Scholar
  19. 20.
    Arguedas M R, Chen V K, Eluobeidi M A, Fallon M B (2003) Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98(3): 679–690PubMedCrossRefGoogle Scholar
  20. 21.
    Stenman U H (2004) Standardization of assays for human chorionic gonadotropin. Clin Chem 50(5): 798–800PubMedCrossRefGoogle Scholar
  21. 22.
    Birken S, Berger P, Bidart J M, Weber M, Britow A, Norman R, Sturgeon C, Stenman U H (2003) Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin Chem 49(1): 144–154PubMedCrossRefGoogle Scholar
  22. 23.
    Huber P R, Bischof P, Kretschmer R, Truschnig M, Halwachs G, Schmidt M (1996) CA 15-3: A multicentre evaluation of automated and manual tests. Eur J Clin Chem Biochem 34: 77–84Google Scholar
  23. 24.
    Veltri R W, Miller M C, O’Dowd G J, Partin A W (2002) Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 60[Suppl 4A]: 47–52PubMedCrossRefGoogle Scholar
  24. 25.
    Cheli C D, Levine R, Cambetas D R, Kolker J D, Roberts S B (2002) Age-related reference ranger for complexed prostate-specific antigen and complexed total prostate-specific antigen ratio: results from east texas medical center cancer institute screening campaign. Urology 60[Suppl 4A]: 53–59PubMedCrossRefGoogle Scholar
  25. 26.
    Ku J H, Kim M E, Lee N K, Park Y H, Ahn J O (2003) Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 61: 132–136PubMedCrossRefGoogle Scholar
  26. 27.
    Minardi D, Galosi A B, Dell’Atti L, Hanitzsch H, Mario P, Muzzonigro G (2002) Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia. Scand J Urol Nephrol 36: 323–329PubMedCrossRefGoogle Scholar
  27. 28.
    Tanguay S, Begin L R, Elhilali M M, Behlouli H, Karakiewicz P I, Aprikian A G (2002) Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 59: 261–265PubMedCrossRefGoogle Scholar
  28. 29.
    Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, Carlini M, Santoro E, Cavaliere R, Greiner J W (1992) CA 72-4 measurement of tumor associated glycoprotein 72 (TAG-72) as a serum marker in the magagement of gastric carcinoma. Cancer Res 52(5): 1222–1227PubMedGoogle Scholar
  29. 30.
    Lai I R, Lee W J, Huang M T, Lin H H (2002) Comparison of serum CA72-4, CEA, TPA, CA 19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49(46): 1157–1160PubMedGoogle Scholar
  30. 31.
    Filella X, Molina R, Jo J, Bedini J L, Joseph J, Ballesta A M (1992) Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer 79(3): 271–277PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2011

Authors and Affiliations

  • Gabriele Halwachs-Baumann
    • 1
  1. 1.Institut für Medizinische und Chemische Labordiagnostik, Krankenhaus SteyrSteyrÖsterreich

Personalised recommendations